Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Corporate Update (November 2025)
26 slides from Vivani Medical's corporate update, Nov 13, 2025
Slide 1: Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.
Slide 2: Disclaimers
= Disclaimers The folowing sides and any accompanying oral presentation contain forward ooking statements within the meaning of Section 27A of the Secures Act of 1933, 35 amended, and Section 21€ ofthe Secures Exchange Act of 1934, as amended, which are intended tobe covered by the "safe harbor” cre
Slide 3: The obesity market is evolving
The obesity market is evolving What wil take to be successful in the future? In addition to the two approved products on the market, there are over 50 in clinical development. All of these are injectables or orals. A differentiated route of administration presents opportunities to access untapped se
Slide 4: Differentiated product candidates designed to address unmet needs and expand the market
Vivani's differentiated product candidates are designed to address unmet needs and expand the market Vivant Market Challenges Suboptimal outcomes Poor medication adherence (<S0%) leads to loss of efficacy and rapid weight rebound Tolerability issues Dose fluctuations and pharmacokinetic (PK) variabi
Slide 5: Vivani Medical, Inc.
Vivani Medical, Inc. A clinical stage innovator uniquely positioned to address the future challenges and opportunities of an evolving obesity market Cour focus: Enhance patient outcomes and GLP-1 market uptake in chronic @ diseases via unique route of administration, improved patent adherence, Nasda
Slide 6: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products may compete in markets with large commercial potential Obesity/Weight ‘Management i ‘Management ES ves
Slide 7: Good things come in small packages
Good things come in small packages GLP-1 implant & applicator NanoPortal device elements NanoPortal technology + Designed to assure adherence + Nanotube pore sie is precisely tunable to achieve near constant release ¥ Long-term defivery profes Stable and tunable release profile. —_ ag a & 4 Simple a
Slide 8: NanoPortal delivers smooth, near-constant drug release
NanoPortal delivers smooth, near-constant drug release In vitro release-rate of exenatide implant (n=6) ‘Day 1 timepoint includes cumulative release over the first day inluding a separately measured Ist hour of ‘release, which wos ~7 jg forthe high-dose and ~4 jg forthe iow-dose. Values are moan = S
Slide 9: In vitro and in vivo performance of 12-week GLP-1 implant configuration
In vitro and in vivo performance of 12-week GLP-1 implant configuration _o| Seemeec —oMean, net? a a oy Soi ee cho sen 2 a 5 my = ° Fo) ry ry ry Tim (Om) Time (oan) Invi relasrat of nna implant nt nich pharmacies of 2 wee xa imple and sham implant in ict estrimepart chet act tne Suneurieanasanca | M
Slide 10: GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study
GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study Liver fat reduction in high fat diet.induced mice. Live fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Values are mean SE Liver fat (% Area) 35.0 300 25.0 200 150 10.0 50 00 ‘Sham Implant
Slide 11: Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects
Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects g., i J 2 s EC aoe! pat 9) vehicle implant (Contr), n= Th 2 Been ‘Time (ays) Time (Oxy) (Weight difference from control in healthy Sprague-Dawley Rats. & weight change rom baseline fora single administration of exena
Slide 12: First-in-human GLP-1 NanoPortal clinical trial
First-in-human GLP-1 NanoPortal clinical ti LIBERATE-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerabilty assessment and full pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization. Otherwise healthy (no T2D, normal renal function) sereen ru 7 unin (8 W
Slide 13: LIBERATE-1 topline results summary
LIBERATE-1 topline results summary Implant well-tolerated No Serious adverse events in the study No clinically meaningful initial burst ‘+ Encouraging release profile 'No evidence of dose dumping Potential for durable long-term delivery confirmed Primary study objectives were met: Further NanoPortal
Slide 14: Vivani Lead Program: NPM-139
Vivani Lead Program: NPM-139 Semaglutide Implant for Chronic Weight Management Targeting the Rapidly Growing GLP-1 Market
Slide 15: Priority clinical development program: NPM-139
Vivens SSraenoieeyers un tseagaties att Priority clinical development program: NPM-139 Development of once- or twice-yearly semaglutide implant for chronic weight management in obese or overweight patients © 2) 19) GLP-1 products Based on real-world The initial program generated >$14B in sales adher
Slide 16: Persistence and adherence are critical to securing desired long-term health outcomes
Persistence and Large Retrospective Cohort Study* (N=1,911) adherence are critical Stmide “Sede to securing desired long-term health — outcomes 75% Persistence data comparing obesity therapies suggest room for improvement across the board, including for semaglutide. 25% © The opportunity for an addi
Slide 17: Semaglutide discontinuation leads to rapid hunger-induced weight rebound
Semaglutide discontinuation leads to rapid hunger- induced weight rebound me see nde (vt) STEP 1 Extension: Semaglutide Withdrawal Wilding eal, 2022 Diabetes, Obesity, and Metabolism
Slide 18: Semaglutide implant delivers durable weight loss in preclinical model for >7 months
Semaglutide implant successfully delivers durable weight loss in preclinical model for >7 months Weight difference versus control group in healthy ‘Sprague-Dawley rats. % weight change from baseline {for NPM.139 (semaglutide implant) corrected to control (sham imoland, Implants from 4 animals were r
Slide 19: Patient and prescriber research indicates strong adoption potential
Patient and prescriber research indicates strong adoption potential for a miniature, 6-month GLP-1 implant 56% of GLP-1 patients responded “likely” ‘Currentiy on a GLP therapy (9328) or “definitely” to get a GLP-1 implant if FDA = approved prescriber recommended and covered by insurance Average pres
Slide 20: NPM-139 clinical and regulatory development: near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins stone Status Announced LIBERATE-1 completed and met the primary study objectives August 2025, Reported positive weight loss in preclinical study with semaglutide eae August 2025 Disclosed proposed clinical program incl
Slide 21: Proposed NPM-139 Phase 1 study design
Proposed NPM-139 Phase 1 study design Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerabilty assessment and pharmacokinetic 18-55 years old: overweight or obese (BMI 27-40) characterization Otherwise healthy (no T20) Screen and Treatment 4Weeks) for anomie (4 day) 7 v Wegovy® (semapl
Slide 22: Proposed NPM-139 Phase 2 study design
—— Proposed NPM-139 Phase 2 study design Vv ‘Rum-in (20 weeks) "y _ Randomized Treatment Period (16 or 24 weeks) nounced 2
Slide 23: The Vivani executive leadership team
The Vivani executive leadership team =) const owre = 3) = : Adam Mendelsohn PhD True Le, MBA (2) Anthony Baldor, MS, MBA fOpersona Oe rr Vivani
Slide 24: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility
Slide 25: Guaranteed adherence. Improved outcomes.
Guaranteed adherence. _ Improved outcomes. © Only GLP-1 implant in development Convenient once- or twice-yearly dosing expected to © address GLP-1 adherence and tolerability challenges Unique modality designed to expand the market by reaching underserved & unaddressed populations 17 as
Slide 26: Thank You
20Ce, Vivani Nasdaq: VANI Thank You ‘Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, Investor Relations Advisor investors@vivani.com